Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Bullboard Posts
Comment by Sonny7on Dec 30, 2019 9:09pm
93 Views
Post# 30503575

RE:Progress

RE:Progresson-target, what you posted is old news but what you posted is valuable. It shows that wallyworld doesn’t pay any attention to anyone’s written words but solely relies on the selfie shooting halfwit to tell him what he wants to hear. He’s not capable of much else, otherwise he wouldn’t post like Gerald McBoing Boing. For clarification, somewhat, that source for wallyworld would be the company’s overpaid paperweight. 

As as I understand it, enrolment is a POTENTIAL trial subject who has signed on some dotted line. When it comes to this enrolee they must eat some sort of meal and then have blood measured to check for c-Peptide markers in the blood. They must NOT show any signs of some form of positive c-Peptide markers (***Anyone, please correct me if I don’t have this correct) from the pancreas, in whole or in part; hence the term “hypoglycaemic unawareness”. If, initially, there are no signs of c-Peptide then they are good to go for trials and will be implanted with the pouch for openers. So, to clarify and again, as I understand it, they may be enrolled but not necessarily implanted with the cell pouch and the subsequent dosage of pancreatic islets as per the FDA Trial criteria. It’s also my understanding that hypoglycaemic unawareness is the worst possible scenario for anyone stricken with this catastrophic disease. Going back, the July 3rd news was monumental in that sense in that it showed that the cell pouch and the islet dosage in that particular trial subject was working to the degree that the islets were thriving right along and acting as they should within the cell pouch in that they showed the presence of c-Peptide. 
So, for all of that, as positive as it may appear......We Wait!!!
Bullboard Posts